• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Skinovation Pharm

Skinovation Pharm

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Enanta Announces U.S. Food and Drug Administration Approves AbbVie’s VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C ...

    Enanta Announces U.S. Food and Drug Administration Approves AbbVie’s VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Virus

  2. Can-Fite Doses First Patient in Global Phase II Liver Cancer Trial for CF102

    Can-Fite Doses First Patient in Global Phase II Liver Cancer Trial for CF102

  3. Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness

    Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness

  4. RXi Pharmaceuticals Issues Open Letter to Shareholders

    RXi Pharmaceuticals Issues Open Letter to Shareholders

  5. Genentech Provides Update on Phase III MARIANNE Study in People with Previously Untreated Advanced HER2-Positive Breast Cancer

    Genentech Provides Update on Phase III MARIANNE Study in People with Previously Untreated Advanced HER2-Positive Breast Cancer

  6. RXi Pharmaceuticals Expands its Clinical Pipeline with an Exclusive Global License for a Second Phase 2 Clinical Compound

    RXi Pharmaceuticals Expands its Clinical Pipeline with an Exclusive Global License for a Second Phase 2 Clinical Compound

  7. RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

    RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

  8. Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant

    Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant

  9. Bayer Appoints Cardinal Health as U.S. Based Contract Manufacturer for Xofigo® (radium Ra 223 dichloride) Injection

    Bayer Appoints Cardinal Health as U.S. Based Contract Manufacturer for Xofigo® (radium Ra 223 dichloride) Injection

  10. Research and Markets: Ostomy and Incontinence Products - 2014 Global Strategic Business Report: Incontinence Products Market to Thrive on Ageing Demographics

    Research and Markets: Ostomy and Incontinence Products - 2014 Global Strategic Business Report: Incontinence Products Market to Thrive on Ageing Demographics

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.